non fda approved glp 1 restricts GLP-1 ingredients in non-approved compounded drugs | FDA posted on the topic New GLP-1 Pill Foundayo (Orforglipron)

Adv Nutr 15, 100291.Google Scholar Landi, F, Calvani, R, Tosato, M et al

What serious side effects mean I should call my doctor

Serious Safety Concerns Associated With Saxenda Severe Gastrointestinal Motility Disorders Reported injuries include: gastroparesis (stomach paralysis) ileus (functional bowel shutdown) severe constipation chronic digestive dysfunction Related: Motility Disorders Dehydration & Kidney Injury Ongoing vomiting or reduced intake may lead to: dehydration electrolyte imbalance acute kidney injury (AKI) worsening kidney disease Related: Dehydration and Kidney Damage Gallbladder Disease Weight loss and altered bile flow may increase the risk of: gallstones gallbladder inflammation gallbladder removal surgery Related: Gallbladder Removal Pancreatitis Some patients report: severe abdominal pain elevated pancreatic enzymes hospitalization for pancreatitis Related: Pancreatitis Vision Problems / NAION Serious vision complications, including Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) , have been reported across the GLP-1 drug class

Additionally, they suppress glucagon secretion from the pancreas, further contributing to improved glycemic control